Aspirin use and the risk for cardiovascular disease by lipoprotein(a) levels: a multi-cohort study
There was no evidence to suggest that the association between aspirin and the incidence of CVD may differ by lipoprotein(a) levels.
Authors
- Mojisola E Fasokun
- Waqas Malick (ORCID: https://orcid.org/0000-0002-6452-9988)
- Ashley Christenson
- Chibuike J Alanaeme (ORCID: https://orcid.org/0000-0003-2792-1259)
- Vera Bittner (ORCID: https://orcid.org/0000-0001-9456-850X)
- Lisandro D. Colantonio (ORCID: https://orcid.org/0000-0001-8742-1788)
- Emily B. Levitan (ORCID: https://orcid.org/0000-0002-5429-3852)
- Lama Ghazi (ORCID: https://orcid.org/0000-0002-9930-3575)
- Medha Dubal
- Zhixin Wang (ORCID: https://orcid.org/0000-0003-2383-1010)
- Robert S. Rosenson
Institutions
- University of Alabama at Birmingham (US)
- Valley Health System (US)
- Mount Sinai Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1093/eurjpc/zwaf547
- Citations
- 4
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.55